B

Beam Therapeutics
D

BEAM

26.440
USD
-2.14
(-7.49%)
مغلق
حجم التداول
62,405
الربح لكل سهم
-5
العائد الربحي
-
P/E
-16
حجم السوق
2,189,380,778
أصول ذات صلة
الأخبار

العنوان: Beam Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making adouble-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.